BIOMARIN PHARMACEUTICAL INC
For the period ended Dec 31, 2024. Filed Feb 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 24, 2025
BMRN$57.13-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
| Page | |
|---|---|
| Exhibit Index | 77 |
| Financial Statements | |
| Report of Independent Registered Public Accounting Firm (KPMG LLP, San Francisco, CA, Auditor Firm ID: 185) | 84 |
| Consolidated Financial Statements as of December 31, 2024 and 2023, and for the three years ended December 31, 2024: | |
| Consolidated Statements of Income | 86 |
| Consolidated Statements of Comprehensive Income | 87 |
| Consolidated Balance Sheets | 88 |
| Consolidated Statements of Stockholders’ Equity | 89 |
| Consolidated Statements of Cash Flows | 90 |
| Notes to Consolidated Financial Statements | 91 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.